Skip to main content

Table 3 Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive symptoms over 52 weeks for patients in the intention-to-treat and per-protocol analysis. Results are adjusted for additional specialized help from mental health services during the first 3 months. Values are means unless stated otherwise. Estimated mean differences and 95% CIs are presented.

From: Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial

  Intention-to-treat MADRS (n = 181)
  Usual care + paroxetine (n = 85) Usual care (n = 96) Mean difference* SD 95% CI
Baseline score 23.8 24.2    
6 weeks – baseline† -7.7 -5.8 -1.9 20.7 -5.0; 1.2
13 weeks – baseline † -10.9 -8.4 -2.5 23.4 -6.1; 1.1
26 weeks – baseline † -13.1 -10.1 -3.0 21.4 -6.4; 0.3
52 weeks – baseline † -14.8 -12.7 -2.1 24.2 -6.2; 1.9
  Per-protocol MADRS (n = 133)
  Usual care + paroxetine (n = 55) Usual care (n = 78) Mean difference* SD 95% CI
Baseline score 25.2 24.1    
6 weeks-baseline† -8.2 -6.5 -1.7 22.1 -5.5; 2.1
13 weeks-baseline† -13.3 -8.7 -4.6 24.3 -8.9; -0.3‡
26 weeks-baseline† -14.0 -9.3 -4.8 20.6 -8.5; -1.0‡
52 weeks-baseline† -17.7 -12.5 -5.2 21.2 -9.2; -1.2‡
  1. *A negative mean difference is a difference in favor of usual care + paroxetine.
  2. †A negative score means a decrease in the severity of symptoms.
  3. ‡The 95% CI of the difference in symptom change lies entirely to the left of zero, indicating statistical significant differences in favor of usual care + paroxetine.